Slide 1: Stock exchange filing cover letter
Biocon Limited 20th KM, Hosur Road Electronic City Bangalore 560 100, India T 91 80 2808 2808 F 91 80 2852 3423 CIN : L24234KA1978PLC003417 www.biocon.com April 1, 2021 To To The Secretary The Secretary BSE Limited National Stock Exchange of India Limited Department of Corporate Services Corporate C
Slide 2: Investor Presentation Q3FY21
INVESTOR PRESENTATION Q3FY21 | January 2021
Slide 3: Safe Harbor Statement
Safe Harbor Statement Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking s
Slide 4: Biocon is a global biopharmaceutical company
Biocon is a global biopharmaceutical company that is leveraging its affordable innovation model to reduce disparities in access to safe, high- quality medicines, as well as, address the gaps in scientific research to find innovative solutions to impact a billion lives. 3
Slide 5: The Biocon Manifesto
The Biocon Manifesto accessibility affordability • Use our science, scale and • Focus on the kind of expertise to enhance access innovation that adds the to essential drugs for condition of affordability to As a committed patients on the lowest rung accessibility stakeholder of the of the economic l
Slide 6: The Biocon Journey: A Continuous Evolution
The Biocon Journey: A Continuous Evolution 1978- 2000- 2005- 2010- 2016- 2019 & 1999 2004 2009 2015 2018 Beyond An Transforming Building the Base Strategic Global Commercialized Poised for Enzymes into a Business and Alliance with Biosimilars for Global Impact Company Biopharma Expertise in Mylan fo
Slide 7: Biocon Today: Strategically poised for a strong global play
Biocon Today: Strategically poised for a strong global play Rs 65,286 Mn 12,000+ Revenue* Total Employees* 1,200+ 25+ Patents cGMP approvals from International regulatory agencies 120+ Ranked 5 Countries where our Among Top 10 Global products are available Biotech Employers by Science magazine *FY20
Slide 8: Business Segments
Business Segments A
Slide 9: Growth Verticals: Aligned With Shifting Paradigms
Growth Verticals: Aligned With Shifting Paradigms From pipeline to production, from drug discovery to drug delivery, we bring differentiated, high-quality and affordable healthcare products & services globally. Ensuring Expanding Partnering to Pushing access access through deliver scientific through
Slide 10: Generics Business - Investing into capacities and capabilities
Generics Business- Investing into capacities and capabilities for the future growth Differentiated API business Growing Formulations Footprint Investments for future growth • 5 state-of-the-art facilities across • Solid oral & parenteral products in both • Expanding our R&D capabilities for newer Ba
Slide 11: Biocon Biologics - Making Global Impact with Biosimilars
Biocon Biologics- Making Global Impact with Biosimilars ‘Pure Play’ Biosimilars Company Fully integrated – lab to market Global Footprint (120+ countries) Strong collaborations (Viatris & Sandoz) Commercial infrastructure in India (BFI) 28 Portfolio 7 Commercial 2 R&D sites 3 Manufacturing sites 25+
Slide 12: Novel Molecules: Pushing scientific boundaries
Novel Molecules: Pushing scientific boundaries to deliver impactful innovations Disease Area Asset Current Progress • Phase I multiple ascending dose studies in Type 1 DM patients making good Insulin Tregopil- a first-in-class oral, prandial progress in Germany.This trial is in partnership with the
Slide 13: Research Services (Syngene): A global CRO
Research Services (Syngene): A global CRO delivering innovative solutions Offering integrated research, development and manufacturing services for both small and large molecules, antibody-drug conjugates and oligonucleotides backed by best-in-class bioinformatic services Combining world class resear
Slide 14: Financial Highlights
Financial Highlights A
Slide 15: Q3FY21 and 9MFY21 Financial Highlights
Q3FY21 and 9MFY21 Financial Highlights Particulars1 Q3 FY21 Q3 FY20 Growth 9M FY21 9MFY20 Growth Total Revenue 1,879 1,753 7% 5,323 4,841 10% EBITDA 427 480 (11%) 1,266 1,383 (8%) EBITDA Margin 23% 27% 24% 29% Core EBITDA Margin 31% 34% 32% 34% Net Profit2 169 206 (18%) 497 645 (23%) Net Profit 169
Slide 16: Revenue by Segments
Revenue by Segments Income1 Q3 FY21 Q3 FY20 Growth 9M FY21 9MFY20 Growth Generics 561 576 (3%) 1,758 1,645 7% Biosimilars 769 693 11% 2,137 1,882 14% Novel Biologics - - - - - - Research Services 585 519 13% 1,526 1,405 9% Revenue from Operations 1,851 1,717 8% 5,267 4,743 11% Other Income 28 36 (22
Slide 17: Key Segment wise highlights
Key Segment wise highlights Segment revenue Q3 FY21 Q3 FY20 Q2 FY21 9M FY21 9M FY20 FY 20 a. Generics 561 576 599 1,758 1,645 2,207 b. Biosimilars 769 693 676 2,137 1,882 2,315 c. Novel Biologics - - - - - - d. Research services 584 519 520 1,526 1,405 2,012 Total 1,914 1,788 1,794 5,421 4,931 6,534
Slide 18: Thank You
Thank You INVESTOR RELATIONS CONTACT: Ankit Gupta, Biocon Limited Tel : +91 813 092 3253 Email: ankit.gupta@biocon.com Nikunj Mall, Biocon Biologics Limited Tel : +91 998 777 4078 Email: Nikunj.mall@biocon.com www.biocon.com 17